InvestorStemCell.com Announces That Apple Inc. (Public, NASDAQ:AAPL) Has Approved IStemcell App

Online, August 3, 2011 (Newswire.com) - The Investor-Stem-Cell iPhone application is now available on iTunes. The name of the application is "iStemcell". The iStemcell application can be purchased on iTunes for $9.99. The iStemcell application is compatible with iPhone, iPod touch and iPAD. Requires iOS or later.

Sai Rosen Director of Client Services for Investor-Stem-Cell commented, "We are committed to providing the most comprehensive website dedicated to the regenerative medicine sector on the web. Bringing stakeholders together in an on-line forum where open debate coupled with education has proved to be a recipe for success. The iStemcell App is in keeping with this ideal. We are providing yet another valuable tool for stem cell investors."

Mr. Rosen went onto to say that the iStemcell Android application is in development and hopes to be available shortly.

The iStemcell application will cover the below companies:

Advanced Cell Technology (OTC:ACTC), Geron Corp. (NASDAQ:GERN), BioTime Inc. (AMEX:BTX),Aastrom Biosciences Inc. (NASDAQ:ASTM), Athersys Inc. (NASDAQ:ATHX), International Stem Cell Corp. (OTC:ISCO), MultiCell Technologies, Inc. (OTC:MCET), StemCells, Inc. (NASDAQ:STEM), ThermoGenesis Corp. (NASDAQ:KOOL), Neostem Inc. (AMEX:NBS), RTI Biologics Inc. (NASDAQ:RTIX), Pluristem Therapeutics Inc. (NASDAQ:PSTI) Bio-Matrix Scientific Group, Inc. (PINK:BMSN), Neostem Inc. (AMEX:NBS) Opexa Therapeutics Inc. (NASDAQ:OPXA), STEM CELL AUTHORITY Ltd. (PINK:SCAL), Brainstorm Cell Therapeutics Inc. (OTC:BCLI), Stem Cell Therapeutics Corp. (CVE:SSS), CRYO-CELL International, Inc. (OTC:CCEL), CellCyte Genetics Corporation (OTC:CCYG), Stem Cell Innovations Inc. (PINK:SCLL). BioMimetic Therapeutics, Inc. (NASDAQ:BMTI), Mesoblast Ltd. (ASX:MSB), Cytori Therapeutics Inc. (NASDAQ:CYTX), SANUWAVE Health, Inc. (OTC:SNWV), Stem Cell Assurance, Inc. (Pink:SCLZ), Proteonomix, Inc. (OTC:PROT), Vitro Diagnostics, Inc. (PINK:VODG), Genesis Biopharma Inc. (OTC:GNBP), Medistem Inc. (PINK:MEDS), Bioheart, Inc. (OTC:BHRT), XYTOS Inc. (PINK:XYTS), ReNeuron Group Plc. (LON:RENE), BioLife Solutions, Inc. (OTC:BLFS), Life Technologies Corp. (NASDAQ:LIFE), China Cord Blood Corp. (NYSE:CO), Talon Therapeutics Inc. (OTC:TLON), RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX) Regenicin, Inc. (OTC:RGIN), RegenoCELL Therapeutics Inc. (OTC:RCLL), American CryoStem Corp. (OTC:CRYO), BIOSTEM US Corp. (PINK:BOSM), Fibrocell Science, Inc. (OTC:FCSC), Shrink Nanotechnologies, Inc. (PINK:INKN), Nuvilex Inc. (PINK:NVLX), Providential Holdings, Inc. (PINK:PHIE), Osiris Therapeutics, Inc. (NASDAQ:OSIR), InoLife Technologies Inc. (PINK:INOL), Intellicell Biosciences Inc. (PINK:SVFC)

Disclosure: Stem Cell Media, LLC., nor any of its companies was compensated for this release. Always consult an investment professional before an investment.